Skip to main content

Investment Year:2019
Transaction Value:€750m

In November 2019, BCEC X acquired a majority stake in Synthon International Holding B.V. (“Synthon” or the “Company”) from the founder, who will remain invested as a minority shareholder.

Synthon is a vertically integrated global leader in the development of complex generics, sharing many similarities with Pharmathen (a BCEC IX deal).

Headquartered in the Netherlands, the Company has c. 1,600 employees and operates four research laboratories and manufacturing sites located in the Czech Republic, Spain, Chile, and Argentina. Synthon is focused on developing, manufacturing and out-licensing complex generics for patients around the world. Founded in 1991 by Dr. Jacques Lemmens, the Company has since developed a diversified base of over 200 customers serving around 100 countries.